Silence Therapeutics PLC (SLN) News

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support...

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg...

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form DEL AM - Delaying amendment

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to...

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence...

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company to...

Mixed Futures Amidst Quiet Economic Schedule; Oil Prices Climb

U.S. index futures displayed varied behavior on Wednesday, following significant gains in the previous session...

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36 Lipoprotein(a) reduction was consistent with phase...